Gram-positive Bacterial Infections Market

Gram-positive Bacterial Infections Market contains market size and forecasts of Gram-positive Bacterial Infections in Global, including the following market information:

• Global Gram-positive Bacterial Infections Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Gram-positive Bacterial Infections market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

B-Lactam Antimicrobials Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gram-positive Bacterial Infections include GlaxoSmithKline, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., AstraZeneca, Astellas Pharma Inc., Novartis AG, Sanofi SA and Sun Pharmaceutical Industries Ltd. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Gram-positive Bacterial Infections companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gram-positive Bacterial Infections Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Gram-positive Bacterial Infections Market Segment Percentages, by Type, 2021 (%)

• B-Lactam Antimicrobials
• Fluoroquinolones
• Penicillin
• Cephalosporins
• RNA Immunoprecipitation (RIP)
• Vaccine
• Other

Global Gram-positive Bacterial Infections Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Gram-positive Bacterial Infections Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Other

Global Gram-positive Bacterial Infections Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Gram-positive Bacterial Infections Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Gram-positive Bacterial Infections revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Gram-positive Bacterial Infections revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• GlaxoSmithKline
• Johnson & Johnson Inc.
• Merck & Co. Inc.
• Pfizer Inc.
• AstraZeneca
• Astellas Pharma Inc.
• Novartis AG
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Cipla